Everolimus dual effects of an area vasculosa angiogenesis and lymphangiogenesis.

Everolimus dual effects of an area vasculosa angiogenesis and lymphangiogenesis.

In Vivo. 2013 Jan;27(1):61-6

Authors: Ceausu RA, Cimpean AM, Dimova I, Hlushchuk R, Djonov V, Gaje PN, Raica M

Abstract
Recently approved as treatment for astrocytoma, kidney and pancreatic cancer, everolimus acts on tumor cells by inhibiting tumor cell growth and proliferation, as well as by inhibition of angiogenic activity by both direct effects on vascular cell proliferation and indirect effects on growth factor production. The effects of everolimus on early stages of normal vasculogenesis, angiogenesis and lymphangiogenesis are not yet available. We found increased development of intravascular pillars by using area vasculosa of the chick chorioallantoic membrane treated with everolimus. An active lymphangiogenic response was highlighted by the expression of Prospero homeobox protein 1 (Prox1) and podoplanin, together with vascular endothelial growth factor receptor C (Vegf-C) and vascular endothelial growth factor receptor 3 (Vegfr-3) expression on day 4 in the treated group. These findings suggest a potential role of everolimus in the activation of lymphangiogenesis.

PMID: 23239853 [PubMed - in process]

c-met inhibitors zm-447439 rad001